Global /China /Healthcare /Drug Manufacturers - General /688443

Chongqing Genrix Biopharmaceutical Co., Ltd.

688443

• SSE: 688443 • Delayed

29.62CNY -3.8%

4.38 USD

As of 15 June 2026, Chongqing Genrix Biopharmaceutical Co., Ltd. has a market cap of $1.67B USD, ranking #7915 globally and #2003 in China. It ranks #662 in the Healthcare sector, and #253 in the Drug Manufacturers - General industry.

Global Rank

7915

Country Rank

2003

Sector Rank

662

Industry Rank

253

Key Stats

Market Cap

$1.67BUSD

11.29B CNY

Enterprise Value

$1.48BUSD

10.02B CNY

Revenue (TTM)

$34.05MUSD

230.73M CNY

EBITDA (TTM)

-$71.82MUSD

-486.05M CNY

Net Income (TTM)

-$79.05MUSD

-535.65M CNY

EBITDA Margin

-211%

Profit Margin

-232%

PS Ratio

48.9

PB Ratio

7.1

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Zhigang Liu open_in_new

Employees

793

Founded

2015

Website

genrixbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.8%	-1.7%	18%	4.4%	3.3%	13%	12%	-36%	-36%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	688443 重庆智翔金泰生物制药股份有限公司 Ordinary Shares - Class A ISIN: CNE100006KG8 Shares Out.: Shares Outstanding: 81.405M¹ Shares Float: 81.394M² TV: TradingView: SSE: 688443 SA: Stock Analysis: SHA: 688443 YF: Yahoo Finance: 688443.SS GF: Google Finance: SHA: 688443 BA: Barron's: 688443 MS: Morningstar: XSHG: 688443	29.62 CNY	TV: TradingView: SSE: 688443 SA: Stock Analysis: SHA: 688443 YF: Yahoo Finance: 688443.SS GF: Google Finance: SHA: 688443 BA: Barron's: 688443 MS: Morningstar: XSHG: 688443

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Chongqing Genrix Biopharmaceutical Co., Ltd.

Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a monoclonal antibody for VZV infection; GR1803, a bispecific antibody for multiple myeloma; GR1901, a bispecific antibody; WM202 a bispecific antibody; WM215, a single-domain antibody; GR1401, an anti-EGFR monoclonal antibody; and GR1405 an anti-PD-L1 monoclonal antibody. The company was founded in 2015 and is based in Chongqing, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.85B 364.89B CNY 3K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.64B 336.36B CNY 3K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.52B 223.48B HKD 2K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 1K%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.51B 111.89B CNY 891%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 860%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 46K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 33K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 22K%	97.4	United States
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 19K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 17K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 16K%	20.5	Switzerland

chevron_leftBack